Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Allows N-9 Products To Stay On Market, Six Months For Label Compliance

Jan 07 2008

• By Katie Stevenson

Related Content

Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA

Jan 20 2003

Additional Topics

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window